Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.

Bavarian Nordic sets up a bout with Valneva’s Ixchiq, the former’s Vimkunya already having an edge in population reach.

Valneva's Ixchiq is the first and only approved Chikungunya vaccine in the US, Canada, and EU. Ixiaro is for Japanese encephalitis, and it’s today VALN’s main revenue contributor. But its near ...

As a bonus, Bavarian Nordic also gets a priority review voucher from the FDA, awarded as an incentive to carry out drug ...

Valneva SE (“Valneva”) announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use ...

and Health Canada 9 to potentially extend the use of IXCHIQ ® to adolescents aged 12 to 17 years. Data from this trial may support regulatory approval of the vaccine in Brazil and other countries ...

and Canada, to expand the use of Ixchiq to patients aged 12 to 17, and now plans to do the same in the UK. This development comes a week after Bavarian Nordic’s vaccine Vimkunya moved closer to ...

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

The single-dose vaccine is indicated for active ... the European Medicines Agency (EMA) and Health Canada 6 to potentially extend the use of IXCHIQ ® to adolescents aged 12 to 17 years.

The vaccine is manufactured at Valneva’s leading vaccine production site in Livingston, Scotland. The approval is based on IXCHIQ®’s final pivotal Phase 3 data, published in The Lancet ...